Details of the Drug

General Information of Drug (ID: DM1SC8M)

Drug Name
Trimipramine
Synonyms
Sapilent; Stangyl; Surmontil; Surmontyl; Trimeprimina; Trimeprimine; Trimeproprimin; Trimeproprimine; Trimipramina; Trimipraminum; Trimeprimina [Italian]; FI 6120; IL 6001; Beta-Methylimipramine; IL-6001; RP-7162; Rhotrimine (TN); Stangyl (TN); Surmontil (TN); Trimipramina [INN-Spanish]; Trimipraminum [INN-Latin]; Trimipramine (USAN/INN); Trimipramine [USAN:INN:BAN]; Trimipramine, (-)-Isomer; (+)-Trimipramine; (-)-Trimipramine; 1-(3-Dimethylamino-2-methylpropyl)-4,5-dihydro-2,3:6,7-dibenzazepine; 10,11 Dihydro-N,N,beta-trimethyl-5H-dibenz(b,f)azepine-5-propanamine; 10,11-Dihydro-5-(3-dimethylamino-2-methylpropyl)-5H-dibenz(b,f)azepine; 10,11-dihydro-N,N,beta-trimethyl-5H-dibenz[b,f]azepine-5-propanamine; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile; 2'-Metil-3'-dimetilamino-propil-5-iminodibenzile [Italian]; 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N,2-trimethylpropan-1-amine; 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine; 5-(3-(Dimethylamino)-2-methylpropyl)-10,11-dihydro-5H-dibenz(b,f)azepine; 5-(gamma-Dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine; 5-(gamma-dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo[b,f]azepine; 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine; 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (+)-(9CI); 5H-Dibenz(b,f)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (-)-(9CI); 7162 RP
Indication
Disease Entry ICD 11 Status REF
Major depressive disorder 6A70.3 Approved [1]
Therapeutic Class
Antidepressants
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 1 Molecular Weight (mw) 294.4
Topological Polar Surface Area (xlogp) 5.8
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Absorption
The drug is rapidly absorbed [2]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 16 mL/min/kg [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 11 - 18 hours [4]
Metabolism
The drug is metabolized via the hepatic [2]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 11.30947 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.051% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 16 L/kg [4]
Chemical Identifiers
Formula
C20H26N2
IUPAC Name
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine
Canonical SMILES
CC(CN1C2=CC=CC=C2CCC3=CC=CC=C31)CN(C)C
InChI
InChI=1S/C20H26N2/c1-16(14-21(2)3)15-22-19-10-6-4-8-17(19)12-13-18-9-5-7-11-20(18)22/h4-11,16H,12-15H2,1-3H3
InChIKey
ZSCDBOWYZJWBIY-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5584
ChEBI ID
CHEBI:9738
CAS Number
3564-75-8
DrugBank ID
DB00726
TTD ID
D00HZV
VARIDT ID
DR00381
INTEDE ID
DR1649
ACDINA ID
D00708

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Norepinephrine transporter (NET) TTAWNKZ SC6A2_HUMAN Inhibitor [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [7]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [8]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [9]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [8]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 06 Mental, behavioural or neurodevelopmental disorder
Disease Class ICD-11: 6A20 Schizophrenia
The Studied Tissue Pre-frontal cortex
The Studied Disease Major depressive disorder [ICD-11:6A20]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Norepinephrine transporter (NET) DTT SLC6A2 7.05E-01 7.02E-03 0.07
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 1.87E-01 4.98E-02 3.61E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 7.66E-01 9.19E-03 4.88E-02
Cytochrome P450 2D6 (CYP2D6) DME CYP2D6 5.64E-01 2.36E-02 1.75E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 7.83E-01 2.32E-03 1.53E-02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Trimipramine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Vilazodone DM4LECQ Major Additive serotonergic effects by the combination of Trimipramine and Vilazodone. Depression [6A70-6A7Z] [54]
Nefazodone DM4ZS8M Major Additive serotonergic effects by the combination of Trimipramine and Nefazodone. Depression [6A70-6A7Z] [54]
Selegiline DM6034S Major Additive serotonergic effects by the combination of Trimipramine and Selegiline. Depression [6A70-6A7Z] [55]
Vortioxetine DM6F1PU Major Additive serotonergic effects by the combination of Trimipramine and Vortioxetine. Depression [6A70-6A7Z] [54]
Isocarboxazid DMAF1NB Major Additive serotonergic effects by the combination of Trimipramine and Isocarboxazid. Depression [6A70-6A7Z] [55]
Milnacipran DMBFE74 Major Additive serotonergic effects by the combination of Trimipramine and Milnacipran. Depression [6A70-6A7Z] [54]
Escitalopram DMFK9HG Major Additive serotonergic effects by the combination of Trimipramine and Escitalopram. Depression [6A70-6A7Z] [56]
Tranylcypromine DMGB5RE Major Additive serotonergic effects by the combination of Trimipramine and Tranylcypromine. Depression [6A70-6A7Z] [55]
Desvenlafaxine DMHD4PE Major Additive serotonergic effects by the combination of Trimipramine and Desvenlafaxine. Depression [6A70-6A7Z] [54]
OPC-34712 DMHG57U Moderate Additive anticholinergic effects by the combination of Trimipramine and OPC-34712. Depression [6A70-6A7Z] [57]
Phenelzine DMHIDUE Major Additive serotonergic effects by the combination of Trimipramine and Phenelzine. Depression [6A70-6A7Z] [55]
Clomipramine DMINRKW Moderate Additive anticholinergic effects by the combination of Trimipramine and Clomipramine. Depression [6A70-6A7Z] [57]
Doxepin DMPI98T Moderate Additive anticholinergic effects by the combination of Trimipramine and Doxepin. Depression [6A70-6A7Z] [57]
Maprotiline DMPWB7T Moderate Additive anticholinergic effects by the combination of Trimipramine and Maprotiline. Depression [6A70-6A7Z] [57]
⏷ Show the Full List of 14 DDI Information of This Drug
Coadministration of a Drug Treating the Disease Different from Trimipramine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Methylene blue DMJAPE7 Major Additive serotonergic effects by the combination of Trimipramine and Methylene blue. Acquired methaemoglobinaemia [3A93] [55]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Trimipramine and Ivosidenib. Acute myeloid leukaemia [2A60] [58]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Midostaurin. Acute myeloid leukaemia [2A60] [59]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Idarubicin. Acute myeloid leukaemia [2A60] [59]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Arn-509. Acute myeloid leukaemia [2A60] [60]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Gilteritinib. Acute myeloid leukaemia [2A60] [61]
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Trimipramine and Oliceridine. Acute pain [MG31] [62]
Scopolamine DMOM8AL Moderate Additive anticholinergic effects by the combination of Trimipramine and Scopolamine. Addictive disorder [6C50-6C5Z] [57]
Mepyramine DMB4SFH Moderate Additive anticholinergic effects by the combination of Trimipramine and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [63]
Phenyltoloxamine DMKAEQW Moderate Additive anticholinergic effects by the combination of Trimipramine and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [63]
Tripelennamine DMZBU15 Moderate Additive anticholinergic effects by the combination of Trimipramine and Tripelennamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [57]
Memantine DMD9WSC Moderate Additive anticholinergic effects by the combination of Trimipramine and Memantine. Alzheimer disease [8A20] [57]
Rivastigmine DMG629M Moderate Antagonize the effect of Trimipramine when combined with Rivastigmine. Alzheimer disease [8A20] [64]
Donepezil DMIYG7Z Moderate Antagonize the effect of Trimipramine when combined with Donepezil. Alzheimer disease [8A20] [64]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Trimipramine and Ivabradine. Angina pectoris [BA40] [60]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Trimipramine and Dronedarone. Angina pectoris [BA40] [59]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Trimipramine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [65]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Cilostazol. Arterial occlusive disease [BD40] [59]
Desipramine DMT2FDC Moderate Additive anticholinergic effects by the combination of Trimipramine and Desipramine. Attention deficit hyperactivity disorder [6A05] [57]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Ofloxacin. Bacterial infection [1A00-1C4Z] [66]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Clarithromycin. Bacterial infection [1A00-1C4Z] [59]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Trimipramine and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [59]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Trimipramine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [66]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [66]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Norfloxacin. Bacterial infection [1A00-1C4Z] [66]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Levofloxacin. Bacterial infection [1A00-1C4Z] [66]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Lomefloxacin. Bacterial infection [1A00-1C4Z] [59]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Telithromycin. Bacterial infection [1A00-1C4Z] [59]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Retigabine. Behcet disease [4A62] [59]
Cariprazine DMJYDVK Moderate Additive anticholinergic effects by the combination of Trimipramine and Cariprazine. Bipolar disorder [6A60] [57]
Loperamide DMOJZQ9 Moderate Additive antimotility effects by the combination of Trimipramine and Loperamide. Bowel habit change [ME05] [67]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Eribulin. Breast cancer [2C60-2C6Y] [59]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Trimipramine when combined with Acetylcholine. Cataract [9B10] [68]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Trimipramine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [69]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Trimipramine and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [70]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Trimipramine and Tiotropium. Chronic obstructive pulmonary disease [CA22] [70]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Trimipramine and Revefenacin. Chronic obstructive pulmonary disease [CA22] [70]
Dihydrocodeine DMB0FWL Moderate Additive serotonergic effects by the combination of Trimipramine and Dihydrocodeine. Chronic pain [MG30] [62]
Levomilnacipran DMV26S8 Major Additive serotonergic effects by the combination of Trimipramine and Levomilnacipran. Chronic pain [MG30] [54]
Olopatadine DMKMWQG Moderate Additive CNS depression effects by the combination of Trimipramine and Olopatadine. Conjunctiva disorder [9A60] [71]
Mestranol DMG3F94 Minor Decreased metabolism of Trimipramine caused by Mestranol. Contraceptive management [QA21] [72]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Halothane. Corneal disease [9A76-9A78] [59]
Remifentanil DMZTXCH Moderate Additive CNS depression effects by the combination of Trimipramine and Remifentanil. Corneal disease [9A76-9A78] [62]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Probucol. Coronary atherosclerosis [BA80] [59]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Clofazimine. Crohn disease [DD70] [73]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Trimipramine and Pasireotide. Cushing syndrome [5A70] [59]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Osilodrostat. Cushing syndrome [5A70] [60]
Ethanol DMDRQZU Moderate Additive CNS depression effects by the combination of Trimipramine and Ethanol. Cystitis [GC00] [74]
Mepenzolate DM8YU2F Moderate Additive anticholinergic effects by the combination of Trimipramine and Mepenzolate. Digestive system disease [DE2Z] [57]
5-hydroxy-L-tryptophan DMDWZGJ Major Additive serotonergic effects by the combination of Trimipramine and 5-hydroxy-L-tryptophan. Discovery agent [N.A.] [75]
Oxybutynine DMJPBAX Moderate Additive anticholinergic effects by the combination of Trimipramine and Oxybutynine. Discovery agent [N.A.] [57]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [59]
Meclizine DMS7T13 Moderate Additive anticholinergic effects by the combination of Trimipramine and Meclizine. Dizziness and giddiness [MB48] [57]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Deutetrabenazine. Dystonic disorder [8A02] [76]
Ingrezza DMVPLNC Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Ingrezza. Dystonic disorder [8A02] [77]
Zonisamide DM0DTF7 Major Additive CNS depression effects by the combination of Trimipramine and Zonisamide. Epilepsy/seizure [8A61-8A6Z] [78]
Stiripentol DMMSDOY Moderate Decreased metabolism of Trimipramine caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [79]
Fosphenytoin DMOX3LB Moderate Decreased metabolism of Trimipramine caused by Fosphenytoin mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [80]
Diphenhydramine DMKQTBA Moderate Additive anticholinergic effects by the combination of Trimipramine and Diphenhydramine. Episodic vestibular syndrome [AB31] [57]
Solifenacin DMG592Q Moderate Additive anticholinergic effects by the combination of Trimipramine and Solifenacin. Functional bladder disorder [GC50] [57]
Mirabegron DMS1GYT Moderate Decreased metabolism of Trimipramine caused by Mirabegron mediated inhibition of CYP450 enzyme. Functional bladder disorder [GC50] [81]
Tolterodine DMSHPW8 Moderate Additive anticholinergic effects by the combination of Trimipramine and Tolterodine. Functional bladder disorder [GC50] [57]
Pentamidine DMHZJCG Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Pentamidine. Fungal infection [1F29-1F2F] [59]
Terbinafine DMI6HUW Moderate Decreased metabolism of Trimipramine caused by Terbinafine mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [82]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Ketoconazole. Fungal infection [1F29-1F2F] [59]
Propantheline DM2EN6G Moderate Additive anticholinergic effects by the combination of Trimipramine and Propantheline. Gastric ulcer [DA60] [57]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [59]
Acetazolamide DM1AF5U Minor as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Trimipramine caused by Acetazolamide mediated altered urine pH. Glaucoma [9C61] [83]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Trimipramine when combined with Pilocarpine. Glaucoma [9C61] [68]
Carvedilol DMHTEAO Moderate Increased plasma concentrations of Trimipramine and Carvedilol due to competitive inhibition of the same metabolic pathway. Heart failure [BD10-BD1Z] [80]
Procarbazine DMIK367 Major Additive serotonergic effects by the combination of Trimipramine and Procarbazine. Hodgkin lymphoma [2B30] [55]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [84]
Cobicistat DM6L4H2 Moderate Decreased metabolism of Trimipramine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [85]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Trimipramine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [86]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [59]
Atazanavir DMSYRBX Moderate Decreased metabolism of Trimipramine caused by Atazanavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [87]
Cinacalcet DMCX0K3 Moderate Decreased metabolism of Trimipramine caused by Cinacalcet mediated inhibition of CYP450 enzyme. Hyper-parathyroidism [5A51] [88]
Givosiran DM5PFIJ Moderate Decreased metabolism of Trimipramine caused by Givosiran mediated inhibition of CYP450 enzyme. Inborn porphyrin/heme metabolism error [5C58] [89]
Belladonna DM2RBWK Moderate Additive anticholinergic effects by the combination of Trimipramine and Belladonna. Infectious gastroenteritis/colitis [1A40] [57]
Amantadine DMS3YE9 Moderate Additive anticholinergic effects by the combination of Trimipramine and Amantadine. Influenza [1E30-1E32] [90]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Trimipramine caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [91]
Propiomazine DMKY8V1 Moderate Increased plasma concentrations of Trimipramine and Propiomazine due to competitive inhibition of the same metabolic pathway. Insomnia [7A00-7A0Z] [92]
ITI-007 DMUQ1DO Moderate Additive anticholinergic effects by the combination of Trimipramine and ITI-007. Insomnia [7A00-7A0Z] [57]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Trimipramine and Polyethylene glycol. Irritable bowel syndrome [DD91] [59]
Clidinium DMUMQZ0 Moderate Additive anticholinergic effects by the combination of Trimipramine and Clidinium. Irritable bowel syndrome [DD91] [57]
Dicyclomine DMZSDGX Moderate Additive anticholinergic effects by the combination of Trimipramine and Dicyclomine. Irritable bowel syndrome [DD91] [57]
Physostigmine DM2N0TO Moderate Antagonize the effect of Trimipramine when combined with Physostigmine. Lips/oral mucosa miscellaneous disorder [DA02] [64]
Glycerol phenylbutyrate DMDGRQO Moderate Decreased metabolism of Trimipramine caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme. Liver disease [DB90-DB9Z] [60]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Trimipramine and Ceritinib. Lung cancer [2C25] [59]
Dacomitinib DMOH8VY Moderate Decreased metabolism of Trimipramine caused by Dacomitinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [93]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Trimipramine and Osimertinib. Lung cancer [2C25] [94]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Trimipramine and Selpercatinib. Lung cancer [2C25] [60]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Trimipramine and Halofantrine. Malaria [1F40-1F45] [95]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Trimipramine and Hydroxychloroquine. Malaria [1F40-1F45] [96]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Primaquine. Malaria [1F40-1F45] [59]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [60]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Trimipramine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [97]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Trimipramine and Vemurafenib. Melanoma [2C30] [59]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Trimipramine and LGX818. Melanoma [2C30] [98]
Ethinyl estradiol DMODJ40 Minor Decreased metabolism of Trimipramine caused by Ethinyl estradiol. Menopausal disorder [GA30] [72]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Trimipramine and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [99]
Flibanserin DM70DTN Moderate Additive CNS depression effects by the combination of Trimipramine and Flibanserin. Mood disorder [6A60-6E23] [100]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Trimipramine and Panobinostat. Multiple myeloma [2A83] [101]
Thalidomide DM70BU5 Moderate Additive CNS depression effects by the combination of Trimipramine and Thalidomide. Multiple myeloma [2A83] [102]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Trimipramine and Siponimod. Multiple sclerosis [8A40] [88]
Ozanimod DMT6AM2 Moderate Additive serotonergic effects by the combination of Trimipramine and Ozanimod. Multiple sclerosis [8A40] [103]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Romidepsin. Mycosis fungoides [2B01] [59]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Trimipramine and Nilotinib. Myeloproliferative neoplasm [2A20] [59]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Dasatinib. Myeloproliferative neoplasm [2A20] [104]
Modafinil DMYILBE Moderate Decreased metabolism of Trimipramine caused by Modafinil mediated inhibition of CYP450 enzyme. Narcolepsy [7A20] [88]
Phenindamine DMDTC7R Moderate Additive anticholinergic effects by the combination of Trimipramine and Phenindamine. Nasopharyngitis [CA00] [57]
Dimenhydrinate DM264B3 Moderate Additive anticholinergic effects by the combination of Trimipramine and Dimenhydrinate. Nausea/vomiting [MD90] [57]
Promethazine DM6I5GR Moderate Increased plasma concentrations of Trimipramine and Promethazine due to competitive inhibition of the same metabolic pathway. Nausea/vomiting [MD90] [92]
Rolapitant DM8XP26 Moderate Decreased metabolism of Trimipramine caused by Rolapitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [105]
Cyclizine DM9G7BS Moderate Additive anticholinergic effects by the combination of Trimipramine and Cyclizine. Nausea/vomiting [MD90] [57]
Granisetron DMIUW25 Major Increased risk of prolong QT interval by the combination of Trimipramine and Granisetron. Nausea/vomiting [MD90] [59]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Trimipramine and Dolasetron. Nausea/vomiting [MD90] [59]
Ondansetron DMOTQ1I Major Additive serotonergic effects by the combination of Trimipramine and Ondansetron. Nausea/vomiting [MD90] [59]
Bupropion DM5PCS7 Major Decreased metabolism of Trimipramine caused by Bupropion mediated inhibition of CYP450 enzyme. Nicotine use disorder [6C4A] [59]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Entrectinib. Non-small cell lung cancer [2C25] [88]
Sibutramine DMFJTDI Major Additive serotonergic effects by the combination of Trimipramine and Sibutramine. Obesity [5B80-5B81] [106]
Lorcaserin DMG6OYJ Major Additive serotonergic effects by the combination of Trimipramine and Lorcaserin. Obesity [5B80-5B81] [107]
Dexfenfluramine DMJ7YDS Major Additive serotonergic effects by the combination of Trimipramine and Dexfenfluramine. Obesity [5B80-5B81] [54]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Trimipramine and Levomethadyl Acetate. Opioid use disorder [6C43] [60]
Lofexidine DM1WXA6 Moderate Additive CNS depression effects by the combination of Trimipramine and Lofexidine. Opioid use disorder [6C43] [60]
Apraclonidine DMO4PVE Moderate Additive CNS depression effects by the combination of Trimipramine and Apraclonidine. Optic nerve disorder [9C40] [108]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Rucaparib. Ovarian cancer [2C73] [59]
Oxymorphone DM65AGJ Moderate Additive serotonergic effects by the combination of Trimipramine and Oxymorphone. Pain [MG30-MG3Z] [62]
Levorphanol DMGS80V Moderate Additive CNS depression effects by the combination of Trimipramine and Levorphanol. Pain [MG30-MG3Z] [62]
Dezocine DMJDB0Y Moderate Additive CNS depression effects by the combination of Trimipramine and Dezocine. Pain [MG30-MG3Z] [62]
Flavoxate DMKV4NL Moderate Additive anticholinergic effects by the combination of Trimipramine and Flavoxate. Pain [MG30-MG3Z] [57]
Nalbuphine DMOSQGU Moderate Additive serotonergic effects by the combination of Trimipramine and Nalbuphine. Pain [MG30-MG3Z] [62]
Buprenorphine DMPRI8G Moderate Additive serotonergic effects by the combination of Trimipramine and Buprenorphine. Pain [MG30-MG3Z] [62]
Hydrocodone DMQ2JO5 Moderate Additive serotonergic effects by the combination of Trimipramine and Hydrocodone. Pain [MG30-MG3Z] [62]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Triclabendazole. Parasitic worm infestation [1F90] [59]
Safinamide DM0YWJC Major Additive serotonergic effects by the combination of Trimipramine and Safinamide. Parkinsonism [8A00] [103]
Rasagiline DM3WKQ4 Major Additive serotonergic effects by the combination of Trimipramine and Rasagiline. Parkinsonism [8A00] [55]
Biperiden DME78OA Moderate Additive anticholinergic effects by the combination of Trimipramine and Biperiden. Parkinsonism [8A00] [57]
Levodopa DMN3E57 Minor Altered absorption of Trimipramine due to GI dynamics variation caused by Levodopa. Parkinsonism [8A00] [109]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Pimavanserin. Parkinsonism [8A00] [110]
Orphenadrine DMW542E Moderate Additive anticholinergic effects by the combination of Trimipramine and Orphenadrine. Parkinsonism [8A00] [57]
Methylscopolamine DM5VWOB Moderate Additive anticholinergic effects by the combination of Trimipramine and Methylscopolamine. Peptic ulcer [DA61] [57]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Famotidine. Peptic ulcer [DA61] [88]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Trimipramine and Macimorelin. Pituitary gland disorder [5A60-5A61] [111]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Trimipramine and Lefamulin. Pneumonia [CA40] [112]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Degarelix. Prostate cancer [2C82] [60]
ABIRATERONE DM8V75C Moderate Decreased metabolism of Trimipramine caused by ABIRATERONE mediated inhibition of CYP450 enzyme. Prostate cancer [2C82] [113]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Enzalutamide. Prostate cancer [2C82] [60]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Relugolix. Prostate cancer [2C82] [60]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Bicalutamide. Prostate cancer [2C82] [60]
Levomepromazine DMIKFEL Moderate Increased plasma concentrations of Trimipramine and Levomepromazine due to competitive inhibition of the same metabolic pathway. Psychotic disorder [6A20-6A25] [92]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Trimipramine and Gatifloxacin. Respiratory infection [CA07-CA4Z] [114]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Quetiapine. Schizophrenia [6A20] [59]
Aripiprazole DM3NUMH Moderate Additive anticholinergic effects by the combination of Trimipramine and Aripiprazole. Schizophrenia [6A20] [57]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Trimipramine and Iloperidone. Schizophrenia [6A20] [59]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Paliperidone. Schizophrenia [6A20] [59]
Perphenazine DMA4MRX Moderate Increased plasma concentrations of Trimipramine and Perphenazine due to competitive inhibition of the same metabolic pathway. Schizophrenia [6A20] [92]
Molindone DMAH70G Moderate Additive anticholinergic effects by the combination of Trimipramine and Molindone. Schizophrenia [6A20] [57]
Thiothixene DMDINC4 Moderate Additive anticholinergic effects by the combination of Trimipramine and Thiothixene. Schizophrenia [6A20] [57]
Trifluoperazine DMKBYWI Moderate Increased plasma concentrations of Trimipramine and Trifluoperazine due to competitive inhibition of the same metabolic pathway. Schizophrenia [6A20] [92]
Risperidone DMN6DXL Moderate Additive anticholinergic effects by the combination of Trimipramine and Risperidone. Schizophrenia [6A20] [57]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Trimipramine and Amisulpride. Schizophrenia [6A20] [115]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Asenapine. Schizophrenia [6A20] [59]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Trimipramine and Pimozide. Schizophrenia [6A20] [60]
Fentanyl DM8WAHT Major Additive serotonergic effects by the combination of Trimipramine and Fentanyl. Sensation disturbance [MB40] [54]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Vardenafil. Sexual dysfunction [HA00-HA01] [59]
Armodafinil DMGB035 Moderate Decreased metabolism of Trimipramine caused by Armodafinil mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [88]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Trimipramine and LEE011. Solid tumour/cancer [2A00-2F9Z] [59]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Trimipramine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [59]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [60]
Doxorubicin DMVP5YE Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [59]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [59]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Lenvatinib. Thyroid cancer [2D10] [59]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Trimipramine and Cabozantinib. Thyroid cancer [2D10] [60]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Trimipramine and Papaverine. Tonus and reflex abnormality [MB47] [116]
Tacrolimus DMZ7XNQ Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Tacrolimus. Transplant rejection [NE84] [59]
Chlorpheniramine DM5URA2 Moderate Additive anticholinergic effects by the combination of Trimipramine and Chlorpheniramine. Vasomotor/allergic rhinitis [CA08] [57]
Methdilazine DMAUHQX Moderate Increased plasma concentrations of Trimipramine and Methdilazine due to competitive inhibition of the same metabolic pathway. Vasomotor/allergic rhinitis [CA08] [92]
Carbinoxamine DMCT31R Moderate Additive anticholinergic effects by the combination of Trimipramine and Carbinoxamine. Vasomotor/allergic rhinitis [CA08] [57]
Trimeprazine DMEMV9D Moderate Increased plasma concentrations of Trimipramine and Trimeprazine due to competitive inhibition of the same metabolic pathway. Vasomotor/allergic rhinitis [CA08] [117]
Brompheniramine DMFOVSD Moderate Additive anticholinergic effects by the combination of Trimipramine and Brompheniramine. Vasomotor/allergic rhinitis [CA08] [57]
Acrivastine DMTIGA0 Moderate Additive anticholinergic effects by the combination of Trimipramine and Acrivastine. Vasomotor/allergic rhinitis [CA08] [57]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Trimipramine and Procainamide. Ventricular tachyarrhythmia [BC71] [59]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Propafenone. Ventricular tachyarrhythmia [BC71] [118]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Trimipramine and Flecainide. Ventricular tachyarrhythmia [BC71] [118]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Trimipramine and Amiodarone. Ventricular tachyarrhythmia [BC71] [59]
⏷ Show the Full List of 186 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
Benzyl alcohol E00010 244 Antimicrobial preservative; Solvent
Butylparaben E00142 7184 Antimicrobial preservative
D&C red no. 28 E00491 6097185 Colorant
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
methylparaben E00149 7456 Antimicrobial preservative
Propyl 4-hydroxybenzoate E00141 7175 Antimicrobial preservative
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Ammonia E00007 222 Alkalizing agent
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol E00011 263 Flavoring agent; Solvent
Edetate calcium disodium E00487 6093170 Complexing agent
Ferrosoferric oxide E00231 14789 Colorant
Gelatin E00630 Not Available Other agent
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Potassium hydroxide E00233 14797 Alkalizing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Sodium propionate E00445 2723816 Antimicrobial preservative
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 23 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Trimipramine 50 mg capsule 50 mg Oral Capsule Oral
Trimipramine 25 mg capsule 25 mg Oral Capsule Oral
Trimipramine 100 mg capsule 100 mg Oral Capsule Oral
Trimipramine Maleate eq 50mg base capsule eq 50mg base Capsule Oral
Trimipramine Maleate eq 25mg base capsule eq 25mg base Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
7 Galactorrhea during treatment with trimipramine. A case report. Pharmacopsychiatry. 2005 Nov;38(6):326-7.
8 Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol. 2003 Oct;23(5):459-66.
9 Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine. Drug Metab Dispos. 2010 May;38(5):863-70.
10 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
11 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
12 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
13 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
14 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
15 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
16 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
17 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
18 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
19 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
20 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
21 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
22 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
23 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
24 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
25 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
26 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
27 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
28 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
29 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
30 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
31 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
32 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
33 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
34 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
35 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
36 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
37 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
38 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
39 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
40 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
41 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
42 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
43 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
44 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
45 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
46 Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
47 Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
48 Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
49 Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
50 Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
51 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
52 Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
53 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
54 Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
55 Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
56 Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6. [PMID: 9562139]
57 Cohen MA, Alfonso CA, Mosquera M. Development of urinary retention during treatment with clozapine and meclizine [published correction appears in Am J Psychiatry 1994 Jun;151(6):952]. Am J Psychiatry. 1994;151(4):619-620. [PMID: 8147469]
58 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
59 Canadian Pharmacists Association.
60 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
61 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
62 Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
63 Kulik AV, Wilbur R "Delirium and stereotypy from anticholinergic antiparkinson drugs." Prog Neuropsychopharmacol Biol Psychiatry 6 (1982): 75-82. [PMID: 7202232]
64 Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC "Explicit criteria for determining inappropriate medication use in nursing home residents." Arch Intern Med 151 (1991): 1825-32. [PMID: 1888249]
65 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
66 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
67 Eronen M, Putkonen H, Hallikainen T, Vartiainen H "Lethal gastroenteritis associated with clozapine and loperamide." Am J Psychiatry 160 (2003): 2242-2243. [PMID: 14638602]
68 Multum Information Services, Inc. Expert Review Panel.
69 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
70 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
71 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
72 Edelbroek PM, Zitman FG, Knoppert-van der Klein EA, van Putten PM, de Wolff FA "Therapeutic drug monitoring of amitriptyline: impact of age, smoking and contraceptives on drug and metabolite levels in bulimic women." Clin Chim Acta 165 (1987): 177-87. [PMID: 3652444]
73 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
74 Ciraulo DA, Alderson LM, Chapron DJ, Jaffe JH, Subbarao B, Kramer PA "Imipramine disposition in alcoholics." J Clin Psychopharmacol 2 (1982): 2-7. [PMID: 7068940]
75 Ciraulo DA, Shader RI "Fluoxetine drug-drug interactions: I. Antidepressants and antipsychotics." J Clin Psychopharmacol 10 (1990): 48-50. [PMID: 1968472]
76 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
77 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
78 Product Information. Zonegran (zonisamide) Elan Pharmaceuticals, S. San Francisco, CA.
79 EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
80 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
81 Product Information. Myrbetriq (mirabegron). Astellas Pharma US, Inc, Deerfield, IL.
82 AbdelRahman SM, Gotschall RR, Kauffman RE, Leeder JS, Kearns GL "Investigation of terbinafine as a CYP2D6 inhibitor in vivo." Clin Pharmacol Ther 65 (1999): 465-72. [PMID: 10340911]
83 Gram LF, Kofod B, Christiansen J, Rafaelsen OJ "Imipramine metabolism: pH-dependent distribution and urinary excretion." Clin Pharmacol Ther 12 (1971): 239-44. [PMID: 5554940]
84 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
85 Product Information. Stribild (cobicistat/elvitegravir/emtricitabine/tenofov). Gilead Sciences, Foster City, CA.
86 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
87 Eap CB, Bender S, Gastpar M, et al "Steady state plasma levels of the enantiomers of trimipramine and its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients." Ther Drug Monit 22 (2000): 209-14. [PMID: 10774635]
88 Cerner Multum, Inc. "Australian Product Information.".
89 Product Information. Givlaari (givosiran). Alnylam Pharmaceuticals, Cambridge, MA.
90 Postma JU, van Tilburg W "Visual hallucinations and delirium during treatment with amantadine (Symmetrel)." J Am Geriatr Soc 23 (1975): 212-5. [PMID: 123540]
91 Product Information. Orladeyo (berotralstat). BioCryst Pharmaceuticals Inc, Durham, NC.
92 Bock JL, Nelson JC, Gray S, Jatlow PI "Desipramine hydroxylation: variability and effect of antipsychotic drugs." Clin Pharmacol Ther 33 (1983): 322-8. [PMID: 6130865]
93 Product Information. Vizimpro (dacomitinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
94 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
95 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
96 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
97 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
98 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
99 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
100 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
101 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
102 Product Information. Thalomid (thalidomide). Celgene Corporation, Warren, NJ.
103 Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
104 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
105 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
106 Chan BSH, Graudins A, Whyte IM, Dawson AH, Braitberg G, Duggin GG "Serotonin syndrome resulting from drug interactions." Med J Aust 169 (1998): 523-5. [PMID: 9861909]
107 Product Information. Belviq (lorcaserin). Eisai Inc, Teaneck, NJ.
108 Product Information. Iopidine (apraclonidine). Alcon Laboratories Inc, Fort Worth, TX.
109 Morgan JP, Rivera-Calimlim L, Messiha F, Sundaresan PR, Trabert N "Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man." Neurology 25 (1975): 1029-34. [PMID: 1237820]
110 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
111 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
112 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
113 Product Information. Zytiga (abiraterone). Centocor Inc, Malvern, PA.
114 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
115 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
116 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
117 Lee BS "Possibility of hyperpyrexia with antipsychotic and anticholinergic drugs." J Clin Psychiatry 47 (1986): 571. [PMID: 3771507]
118 Katz MR "Raised serum levels of desipramine with the antiarrhythmic propafenone ." J Clin Psychiatry 52 (1991): 432-3. [PMID: 1938981]